Genes in Focus
The Biobank is returning results for 3 pharmacogenetic (PGx) genes: CYP2C19, SLCO1B1 & DPYD.
Pharmacogenetic Results
Results that may predict response to medications. Information for healthcare professionals.
Overview of Pharmacogenetic Return of Results
Pharmacogenetics (PGx) is the use of genetic information to help guide drug selection and dosing.
The Colorado Center for Personalized Medicine is enrolling participants in a research Biobank, primarily focused on genetics.
Biobank participants may give permission to return available genetic test results, including select, clinically-actionable PGx test results to their UCHealth electronic health record (EHR).
Prerequisites for Return
In order for results to be available to providers, a Biobank participant must have a blood or saliva sample collected and processed and sign appropriate consent for return.Scroll down to see FAQs
Drug-Gene Pairs
Biobank participants who have provided a sample for genotyping and consented to receive results may receive results if they are available. For pharmacogenetic results, participants will be notified via UCHealth's MyHealthConnection patient portal. The date that these results file into the EHR is the date that the sample was initially collected, which may be several years before notification that results are now available. If you or your patient is having a hard time finding their results, please scroll back several years in the EHR to identify Biobank results.
No. However, CCPM has embedded clinical decision support (CDS) tools into UCHealth’s EHR to notify clinicians of gene-drug interactions at the time of prescribing. As of December 2021, clinical decision support is available for 17 drug-gene pairs affected by variation in CYP2C19 or SLCO1B1.
Please note that not all medications are metabolized by CYP2C19 or transported by SLCO1B1. For medications that are metabolized by CYP2C19, CYP2C19 genotype does not impact outcomes for all medications to the same extent, or does so in an indication-specific manner. For medications that are transported by SLCO1B1, SLCO1B1 genotype does not impact outcomes for all medications to the same extent.
For further information, please visit the drug-gene specific resources and tip sheets below. Additional information can be found on the UCHealth Provider Portal.
For general information about CYP2C19, click here.
For general information about SLCO1B1, click here.
The Colorado Center for Personalized Medicine (CCPM) is currently returning CYP2C19 & SLCO1B1 genotype results to Colorado Biobank participants. In order to receive a Biobank pharmacogenetic test result, a participant must sign a consent form agreeing that results can be placed in his or her electronic health record (EHR). After this consent form is signed, results may then be placed into the participant’s EHR and sent to him or her via UCHealth’s MyHealthConnection patient portal (if results are available for the participant). Other pharmacogenetic test results will be released in a step-wise approach. Please check back for updates.
Colorado Center for Personalized Medicine
University of Colorado Anschutz Medical Campus
CU Anschutz
Anschutz Health Sciences Building
1890 N Revere Ct
Mailstop F563
Aurora, CO 80045
CMS Login